Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic.
Souza JDS, Zuardi AW, Guimarães FS, Osório FL, Loureiro SR, Campos AC, Hallak JEC, Dos Santos RG, Machado Silveira IL, Pereira-Lima K, Pacheco JC, Ushirohira JM, Ferreira RR, Costa KCM, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Andraus MH, Crippa JAS. Souza JDS, et al. Among authors: fonseca bal. Front Pharmacol. 2022 Oct 3;13:856846. doi: 10.3389/fphar.2022.856846. eCollection 2022. Front Pharmacol. 2022. PMID: 36263136 Free PMC article.
Efficacy and Safety of Cannabidiol Plus Standard Care vs Standard Care Alone for the Treatment of Emotional Exhaustion and Burnout Among Frontline Health Care Workers During the COVID-19 Pandemic: A Randomized Clinical Trial.
Crippa JAS, Zuardi AW, Guimarães FS, Campos AC, de Lima Osório F, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Pacheco JC, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Pereira-Lima K, Sen S, Andraus MH, Hallak JEC; Burnout and Distress Prevention With Cannabidiol in Front-line Health Care Workers Dealing With COVID-19 (BONSAI) Trial Investigators. Crippa JAS, et al. Among authors: fonseca bal. JAMA Netw Open. 2021 Aug 2;4(8):e2120603. doi: 10.1001/jamanetworkopen.2021.20603. JAMA Netw Open. 2021. PMID: 34387679 Free PMC article.
Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Crippa JAS, Pacheco JC, Zuardi AW, Guimarães FS, Campos AC, Osório FL, Loureiro SR, Dos Santos RG, Souza JDS, Ushirohira JM, Ferreira RR, Mancini Costa KC, Scomparin DS, Scarante FF, Pires-Dos-Santos I, Mechoulam R, Kapczinski F, Fonseca BAL, Esposito DLA, Passos ADC, Dal Fabbro AL, Bellissimo-Rodrigues F, Arruda E, Scarpelini S, Andraus MH, Nather Junior JC, Wada DT, Koenigkam-Santos M, Santos AC, Busatto Filho G, Hallak JEC. Crippa JAS, et al. Among authors: fonseca bal. Cannabis Cannabinoid Res. 2022 Oct;7(5):658-669. doi: 10.1089/can.2021.0093. Epub 2021 Oct 7. Cannabis Cannabinoid Res. 2022. PMID: 34619044 Free PMC article. Clinical Trial.
Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial.
Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, Gigante SL, Benatti MN, Rezek UC, Emrich-Filho LL, Sousa BAA, Almeida SCL, Luppino Assad R, Veras FP, Schneider A, Rodrigues TS, Leiria LOS, Cunha LD, Alves-Filho JC, Cunha TM, Arruda E, Miranda CH, Pazin-Filho A, Auxiliadora-Martins M, Borges MC, Fonseca BAL, Bollela VR, Del-Ben CM, Cunha FQ, Zamboni DS, Santana RC, Vilar FC, Louzada-Junior P, Oliveira RDR. Lopes MI, et al. Among authors: fonseca bal. RMD Open. 2021 Feb;7(1):e001455. doi: 10.1136/rmdopen-2020-001455. RMD Open. 2021. PMID: 33542047 Free PMC article. Clinical Trial.
Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients.
Amaral NB, Rodrigues TS, Giannini MC, Lopes MI, Bonjorno LP, Menezes PISO, Dib SM, Gigante SLG, Benatti MN, Rezek UC, Emrich-Filho LL, Sousa BA, Almeida SCL, Luppino-Assad R, Veras FP, Schneider AH, Leiria LOS, Cunha LD, Alves-Filho JC, Cunha TM, Arruda E, Miranda CH, Pazin-Filho A, Auxiliadora-Martins M, Borges MC, Fonseca BAL, Bollela VR, Del-Ben CM, Cunha FQ, Santana RC, Vilar FC, Zamboni DS, Louzada-Junior P, Oliveira RDR. Amaral NB, et al. Among authors: fonseca bal. Inflamm Res. 2023 May;72(5):895-899. doi: 10.1007/s00011-023-01718-y. Epub 2023 Mar 14. Inflamm Res. 2023. PMID: 36917217 Free PMC article. Clinical Trial.
Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC, Pires da Silva BGP, Fonseca BAL, Fonseca NP, Auxiliadora-Martins M, Mastaglio S, Ruggeri A, Sironi M, Radermacher P, Chrysanthopoulou A, Skendros P, Ritis K, Manfra I, Iacobelli S, Huber-Lang M, Nilsson B, Yancopoulou D, Connolly ES, Garlanda C, Ciceri F, Risitano AM, Calado RT, Lambris JD. Mastellos DC, et al. Among authors: fonseca bal, fonseca np. Clin Immunol. 2020 Nov;220:108598. doi: 10.1016/j.clim.2020.108598. Epub 2020 Sep 19. Clin Immunol. 2020. PMID: 32961333 Free PMC article.
112 results